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Astrocytes have the ability to modulate neuronal excitability and synaptic transmission by the release of gliotransmitters. The
importance of ATP released downstream of the activation of Gq-coupled receptors has been well established, but the mechanisms
by which this release is regulated are unclear. The current work reveals that the elevation of diacylglycerol (DAG) in astrocytes
induces vesicular ATP release. Unexpectedly, DAG-induced ATP release was found to be independent of PKC activation, but
dependent upon activation of a C1 domain-containing protein. Astrocytes express the C1 domain-containing protein Munc13-1,
which has been implicated in neuronal transmitter release, and RNAi-targeted downregulation of Munc13-1 inhibits astrocytic
ATP release. These studies demonstrate that elevations of DAG induce the exocytotic release of ATP in astrocytes, likely via a
Munc13-1-dependent mechanism.
1.Introduction
The role of astrocyte gliotransmission in the modulation of
neuronal signaling has been reported upon with increasing
frequency within the last decade [1–3]. Astrocytes have
been shown to release gliotransmitters, including glutamate
and D-serine, via vesicular exocytosis [2, 4–10], which
inﬂuence synaptic properties [1, 9]. In addition, astrocytic
ATP release plays important roles in synaptic plasticity [1,
11–13]althoughthecellsignalingeventsprecedingitsrelease
are currently unclear [14].
Astrocytes express class I metabotropic glutamate recep-
tors (mGluRs), which can induce gliotransmission in
response to neuronal glutamate [15–17]. Previous work
has shown that activation of astrocytic mGluR5 modulates
neurotransmission in the nucleus accumbens [18]. mGluR5
receptors are G-protein-coupled receptors (GPCRs) that
signal via the Gq and phospholipase C (PLC) signaling
pathway, in which the small signaling molecules 1,4,5-
trisphosphate (IP3) and diacylglycerol (DAG) are produced,
and IP3-stimulated calcium release is eﬀected from internal
stores.TheDAGanalogue1-oleoyl-2-acyl-sn-glycerol(OAG)
has been found to induce calcium oscillations in astrocytes
in a PLC-dependent manner through an undeﬁned pathway
[19]. This ﬁnding suggests that gliotransmission may be
eﬀected via activation of the DAG arm of the Gq signal-
ing pathway, although the mechanism responsible for the
observed calcium oscillations is not clear.
ATP is released from astrocytes in the brain where
it is rapidly converted to adenosine in the perisynaptic
space through the actions of ectonucleotidases [20]. This
adenosine acts to tonically inhibit synaptic transmission
through activation of presynaptic A1 receptors [1]. Trans-
genic animals with impaired SNARE-dependent astrocytic
ATP release demonstrate that adenosine, converted from
astrocytic ATP, suppresses neuronal excitability and leads
to heterosynaptic depression [1, 21]. In addition to serving
physiological roles, astrocytes can contribute to excita-
tion underlying seizures [22], although the precise role
of gliotransmitters remains to be determined. Adenosine,
acting through A1 receptors, causes a reduction in neuronal
excitability and in excitatory synaptic transmission [23].
So powerful are these actions that small-molecular-weight
adenosine analogs have been proposed as anticonvulsants
(for review see [24]). However, their systemic actions limit
theireﬀectiveuseastherapeutics.Thus,theelucidationofthe2 Neural Plasticity
intracellular signaling pathways connecting the activation of
Gq GPCRs, like mGluR5, to astrocytic ATP gliotransmission
provides new targets for the therapeutic manipulation of
neuronal excitability. In the current work, I provide evidence
that activation of the DAG pathway in astrocytes leads to
exocytotic ATP release.
2.MaterialsandMethods
2.1. Reagents. OAG was purchased both in solid form from
Biomol (Plymouth Meeting, Pa) and as a solution in acetoni-
trile from Cayman Chemical (Ann Arbor, Mich). For short-
term storage (less than 2 weeks), solid OAG was dissolved
in fresh DMSO to 60mM and stored under nitrogen in
screw-top tubes at −80◦C. To prepare for use, aliquots in
DMSOwerethawedatroomtemperatureandsonicatedfor5
minutes. The OAG was then added to warm (∼37◦C–42◦C)
normal hippocampal saline (NHS; concentrations (in mM)
140NaCl,5KCl,2CaCl2,2MgSO 4,10HEPES,10D-glucose,
and 6 Sucrose, pH = 7.35) and vortexed well. For longer-
termstorage(upto2months),OAGinacetonitrilewasdried
under nitrogen in 1mg aliquots and stored under nitrogen
at −80◦C. Fresh, warm DMSO was added to make 60mM
OAG, and this solution was sonicated for 5 minutes before
being added to warmed NHS as above. Final concentrations
ofboth30µMand100µMofOAGinNHSwereusedinthese
experiments. OAG solutions were maintained at or above
room temperature, to maintain the solubility of the OAG.
Other experimental reagents included 1-Stearoyl-2-ara-
chidonoyl-sn-glycerol (SAG, 60mM stock in DMSO, Bio-
mol), Suramin (stock fresh in H2O, Sigma, St. Louis,
Min, USA), pyridoxalphosphate-6-azophenyl-2
 ,4
 -disulph-
onic acid (PPADS, stock fresh in H2O, Tocris, Ellisville,
Min), Baﬁlomycin A1 (100µM stock in DMSO, Biomol),
Carbenoxolone (80mM stock in H2O, Sigma), GF 109203X
(Bisindolylmaleimide I, 20mM in DMSO, BioSource,
Camarillo, Calif, USA), Calphostin C (10mM stock in
DMSO, Biomol), ATP (made fresh in NHS, Sigma), Apyrase
(50U/mL stock in H2O, Sigma), RHC-80267 (60mM stock
in DMSO, Biomol), R59949 (25mM stock in DMSO,
Calbiochem, San Diego, CA, USA). Nominally calcium-free
NHS contained about 60nM of calcium to prevent calcium
eﬄux from astrocyte internal stores.
The OAG used in the experiments was conﬁrmed to
be free from contamination by ATP using the luciferin-
luciferase luminescence reaction. NHS containing 30µM
and 100µM OAG was combined with Sigma’s ATP assay
reaction mix (FLAAM) and assayed for luminescence using
a Synergy 2 Luminometer from Biotek (Winooski, Vt, USA).
An absence of luminescence in the OAG samples conﬁrmed
that they were not contaminated with ATP.
2.2. Culture of Primary Cortical Astrocytes. Cortical astro-
cytes from neonatal C57/Bl6 mice were cultured as described
previously in [7, 8]. After 2 weeks in culture, astrocytes were
plated onto coverslips coated with 10µg/mL poly-D-lysine
and cultured in regular MMEM for 7 to 21 days before
imaging. Prior to imaging, coverslips were washed with
normal hippocampal saline and incubated for 40 minutes
at room temperature with Fluo-4 (Invitrogen, Carlsbad, CA)
in NHS (5µg/mL Fluo-4 with 1:1000 20% Pluronic acid in
DMSO). Nominally Ca2+-free NHS was composed as follows
(concentrations (in mM) 140 NaCl, 5 KCl, 1 CaCl2,2E G T A ,
2.15 MgSO4, 10 HEPES, 10 D-glucose, and 6 Sucrose). The
ﬁnal concentration of free external calcium was estimated to
be 60nM. For experiments using Baﬁlomycin A1, cells were
incubated with 100nM Baﬁlomycin A1 or the equivalent
amount (0.1%) of DMSO for 45 minutes at 37◦C and then
for an additional 45 minutes at room temperature with the
addition of Fluo4. For experiments using Calphostin C, cells
were incubated for 15 minutes following t1 with 100nM of
Calphostin C under room lights to activate the compound,
and lights were then turned oﬀ for imaging.
2.3. Imaging. Coverslips were placed on the stage of an
epiﬂuorescence microscope equipped with a cooled digital
camera (ORCA, Hamamatsu) controlled by Image-Pro soft-
ware with custom-build function (Phase 3 Imaging Systems,
Pa, USA). All experiments were done in NHS with perfusion
kept at 33◦C with an in-line solution heater.
Time series experiments consisted of three series of 200
time-lapse images (t1, t2, and t3) separated by 15-minute
rinses in NHS. The interval between frames was approxi-
mately5seconds. Mostpharmacologicalmanipulations were
added during the t2 interval. Image stacks were analyzed
using the Metamorph software package. Fluorescence inten-
sities were then measured on image stacks, and data was
exported to and analyzed in MS Excel. Measurements shown
include F/F0 (increase in ﬂuorescence over baseline) and the
percentage of astrocytes in a ﬁeld with F/F0 > 2( %c e l l s
responding).
2.4. Immunostaining. Immunocytochemistry was perfor-
med on astrocytes plated, as above, on coverslips and
ﬁxed with 4% paraformaldehyde for 20 minutes at room
temperature. Coverslips were incubated in blocking buﬀer
(50mM NH4Cl containing 2% BSA, 2% glycine, and 0.2%
gelatin) for 15 minutes at RT. To localize Munc13-1 protein,
coverslips were incubated in aﬃnity-puriﬁed rabbit poly-
clonal anti-Munc13-1 (1:100, Synaptic Systems) in blocking
buﬀer for 48 hours at 4◦C followed by the secondary
antibody (goat antirabbit IgG-Alexa 588, 1:500, Invitrogen)
for 1 hour at room temperature. Coverslips were mounted
onto microscope slides with Vectashield Hardset mounting
medium with DAPI (Vector Labs). Images were taken at
20x on a Nikon A1 confocal laser microscope and color-
combined in Metamorph.
2.5. Western Blotting. Protein used for Western blotting
was extracted from conﬂuent astrocyte cultures in 10cm
dishes. Cells were rinsed with PBS and snap-frozen on
dry ice; protein was then extracted with Pierce’s M-PER
extraction buﬀer (Pierce) containing protease inhibitors
(Halt Protease Inhibitor, Fisher) and quantiﬁed using the
Bio-Rad protein assay. For positive controls, cultured mouse
cortical neurons were similarly processed. Sixty micrograms
of astrocytic protein or 15µg of neuronal, was loaded onto
each lane of a 7% Tris-Acetate gel (NuPage, Invitrogen).Neural Plasticity 3
Following electrophoresis, proteins were transferred to
Hybond C extra nitrocellulose membranes (Amersham
Biosciences), blocked with 4% nonfat milk in TBS buﬀer
containing 0.05% Tween-20 (TBST). Membranes were then
cut in half to make a high-MW membrane (containing
Munc13-1, 200kD) and a low-MW membrane (containing
GAPDH, 36kD). The high-MW membrane was incubated
overnight at 4◦Cw i t hr a b b i tp o l y c l o n a la n t iM u n 1 3 - 1
(Synaptic Systems) used at 1:500 in TBST. The low-MW
membranewasincubatedovernightwithmousemonoclonal
anti-GAPDH (Fisher) at 1:1000. Membranes were then
washed in TBST and incubated for 1 hour in secondary
antibody (goat antirabbit-HRP 1:5000, goat anti-mouse-
HRP Pierce 1:3000). Immunoreactive bands were detected
by exposing membranes to Amresco VisiGlo HRP-plus
chemiluminescent substrate for 5 minutes (Amresco, Solon,
OH) and imaging with the LAS 3000 luminescence imag-
ing system (Fuji Film). Quantitative Western blotting was
performed by quantifying Munc13-1 optical density as a
proportion of GAPDH using ImageJ software (NIH).
2.6. siRNA. Silencer Select predesigned siRNAs against
mouse Munc13-1 (NM 0010298873) were obtained from
Ambion (Austin, Tex, USA) and resuspended in RNAse-
free sterile water to make a 20µMs t o c kw h i c hw a ss t o r e d
at −80◦C. Primary astrocytes on 10cm plates or coverslips
were transfected with 3.2µg/mL siRNAs in culture with
the TransMessenger transfection reagent (Qiagen, Valencia,
CA, USA). Silencer Negative Control no.1 siRNAs and
Silencer Cy3-labeled Negative Control no.1 siRNAs, both
fromAmbion,wereusedascontrols.Examinationofcultures
transfected with Cy3-labeled siRNAs demonstrated a near
100%transfectioneﬃciencyofthesiRNAs(datanotshown).
Seven days after transfection astrocyte protein was collected
from the 10cm plates as described above. Western Blot anal-
ysis demonstrated a moderate (30%) reduction of Munc13-
1 protein in astrocytes transfected with Munc13-1 siRNAs
compared with negative control siRNAs. Five to 7 days after
transfection,siRNA-transfectedastrocytesoncoverslipswere
imaged for OAG response as described above.
2.7. RT-PCR, Cloning, and Sequencing of Mun13-1. PCR
primersweremadeagainstaportionofthecodingdomainof
mouse Munc13-1 (GenBank NM 001029873). Five hundred
nanograms of RNA extracted from mouse cortical astrocytes
with Trizol reagent was subjected to reverse transcrip-
tion using Qiagen Omniscriot RT (Qiagen, Valencia, CA).
With the primers described above, PCR was performed
using Qiagen HotStar Taq (Figure 6(c)). The resultant PCR
product was cloned into the pGEMT-Easy cloning vector
(Promega) and transformed into XL-1 blue competent
cells (Stratagene, La Jolla, CA). Blue/white screening on
LB/AMP plates determined positive colonies which were
maxiprepped and the inserts conﬁrmed by restriction digest.
Several inserts were sequenced using M13 forward and
reverse primers on an Applied Biosystems (ABI; Foster City,
CA) 3130XL sequencer. Resultant sequences were aligned
with NM 001029873 using DNAStar MegAlign software
(Madison, Wis) and 100% homology was conﬁrmed.
2.8. Luciferase Assays. Astrocytes were subcultured into the
inner wells of 96-well Corning white, clear-bottomed assay
plates (Corning Inc, Corning, NY, USA) at 16,000cells/well.
Outer wells contained sterile water to prevent uneven
evaporation during culturing. Plates were brought to an
incubator adjacent to the luminometer (Synergy2, BioTek,
Winooski, Vt, USA) at least 24 hours prior to assay to
prevent unnecessary motion. Astrocytes were rinsed once
with 50µL of warmed NHS and rested for 40 minutes at
room temperature. Following the addition of 60µMO A G
in 50µL NHS (ﬁnal concentration = 30µM), plates were
incubated at 34◦C for 20 minutes inside the luminometer.
Luciferase assay solution was made by adding 450µLo f
NHS and 50µL of water to Sigma’s ATP bioluminescence
FLAAM assay reagent and incubating on ice for one hour. To
assay for ATP release, 50µL of luciferase assay solution was
injected into each well, and relative light units (RLUs) were
recorded by the luminometer for a continuous 20 minutes.
Data was analyzed as an integral over 20 minutes (sum
RLUs). Following each assay, the wells were emptied and
plates were snap-frozen. Protein assays were conducted on
the assay plates by adding 200µL of the Pierce BCA Protein
AssayReagentA:ReagentB(1:50)mix(Pierce,Rockford,IL,
USA) to the wells containing either cells or a BSA standard
curve and incubated for 15 minutes at 37◦C. Plates were then
read using a BioRad Model 680 microplate reader (BioRad,
Hercules, CA, USA) at 570nm. Using the standard curve,
the protein content of each well was estimated and used
to normalized the integrated RLU measure. The control
(DMSO) samples from each plate were randomized into two
groups, “test” and “standard,” and the percent control was
calculated as a percentage of the DMSO standard value.
3. Results
3.1. Experimental Design. To further examine the mecha-
nisms underlying OAG-stimulated ATP release in astrocytes,
Iusedalivecalciumimagingapproach.Eachimagingsession
consisted of one coverslip imaged in three separate time
periods (t1, t2, and t3) in a contiguous experiment. T1
served as a baseline control measuring the response of the
astrocytes to OAG. After a 15-minute wash period, t2s e r v e d
as the experimental session where the response to OAG was
examined in the presence of various drugs. After another
15-minute wash period, the t3 imaging period was used to
examine recovery of the astrocyte response to OAG.
3.2. OAG Induces Calcium Oscillations in Astrocytes. Similar
to Hisatsune et al., I found that the application of OAG
induced calcium oscillations in astrocytes (Figures 1(a),
1(b)–1(d)). This response was dose dependent, being more
robust in the presence of 100µM OAG as compared to 30µM
OAG (data not shown). Figures 1(b)–1(d) show 1-minute
collapsed reconstructions of the cells represented by the
tracesinFigure 1(a).InFigures1(b)–1(d),andSupplemental
Figure1thecalciumsignalcanbeseenasdiscreetoscillations
represented by the appearance of high Fluo4 signals (yellow-
red) in noncontiguous cells in separate regions of the
imaging ﬁeld. The calcium response persists in nominally4 Neural Plasticity
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Figure 1: The diacylglycerol analogue 1-oleoyl-2-acyl-sn-glycerol (OAG) induces calcium oscillations in astrocytes that are not dependent
on external calcium. (a) Cultured cortical astrocytes respond to 100µM OAG with robust calcium oscillations. (b) Astrocytes imaged
in culture in a perfusion system have little background calcium activity as imaged with Fluo4. (c) The addition of 100µMO A Gc a u s e s
increases in the Fluo4 signal in discrete astrocytes but does not result in a calcium wave. (d) Astrocyte calcium oscillations continue for
several minutes after the OAG-containing medium is washed away. (e) Calcium oscillation in response to 30µM OAG is not reduced in the
presence of nominally (∼60nM) calcium-free external medium (P = 0.25, n = 5). (f) The astrocyte response to 30µM OAG is signiﬁcantly
greater than the response to the less cell-permeable DAG analogue 1-stearoyl-2-arachidonyl-sn-glycerol (SAG, 30µM) (P = 0.0002, control
n = 14, SAG n = 6).Neural Plasticity 5
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Figure 2: OAG-dependent calcium oscillations in cultured astrocytes are a result of ATP release. (a) During the ﬁrst imaging period (t1) a
baseline response to 100µM OAG is established in astrocyte cultures. Data are shown as individual cell traces of F/F0 (fold change) over time
(minutes).BlockingastrocyticATPreceptorsduringthesecondimagingperiod(t2)withacombinationoftheP2receptorinhibitorsPPADS
and Suramin greatly reduces the response to 100µM OAG. This blockade is reversible, after washout the response to 100µM is reestablished
in the third imaging period (t3). Diagonal lines between imaging session indicate a wash period of 15 minutes occurring between imaging
sessions. (b) Addition of the enzyme apyrase, which degrades ATP to ADP, and ADP to AMP, during t2 abolishes the astrocytic response
to 100µM OAG. (c) Quantiﬁcation demonstrates a signiﬁcant decrease in the percentage of astrocytes responding with calcium oscillations
to OAG stimulation with either the blockade of ATP receptors (PPADS/Suramin; control n = 5, PPADS/Suramin n = 8; t2 P = 0.02) or
the degradation of extracellular ATP (Apyrase; control n = 5, apyrase n = 4; t2 P = 0.02). (d) ATP assays performed with the luciferin-
luciferase reaction demonstrate the release of ATP from cultured astrocytes treated with OAG, compared to controls with DMSO added
(DMSO n = 29, OAG = 27, P = 0.001).
calcium-free external solution, indicating that internal stores
are the source of the calcium oscillations (Figure 1(e)). The
speciﬁcity of this response to OAG was insured by use
of the DAG analogue 1-stearoyl-2-arachidonyl-sn-glycerol
(SAG),whichpermeatesthecellmembranemuchlessreadily
than OAG, and therefore shows an attenuated response
(Figure 1(f)).
3.3. Astrocytes Release ATP in Response to OAG Applica-
tion. I used the luciferase-luciferin reaction to examine6 Neural Plasticity
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Figure 3: Blockade of DAG metabolites does not inhibit astrocytic
ATP release. Inhibition of DAG kinase with 10µM R59945 causes
an increase in astrocytic calcium oscillations in response to 30µM
OAG (control n = 13, R5 n = 5; P = 0.016). Inhibition of DAG
lipase with 50µM RHC80267 had no eﬀect on astrocyte ATP release
(control n = 6, RHC = 9; P = 0.3).
OAG-stimulated astrocytes via luminometry. Astrocytes cul-
tured in 96-well plates (n = one plate) released signiﬁcantly
more ATP in response to 30µM of OAG than an addition
of an equal volume of NHS containing 0.05% DMSO
(Figure 2(d)). These results indicate that stimulation of the
DAG arm of the Gq pathway leads to ATP release in cultured
astrocytes.
3.4. Calcium Oscillations Are Induced by Activation of P2
Receptors by ATP. To test the hypothesis that the OAG-
induced calcium oscillations were being induced in a
paracrine manner by astrocytic ATP release, I used the ATP
receptor blockers PPADS and Suramin in combination to
block both P2Y and P2X receptors expressed in the cultured
astrocytes. The astrocytic response to OAG was greatly
diminished in the presence of ATP receptor antagonists
(Figure 2(a)), indicating that the calcium response observed
is downstream of ATP receptor activation. The enzyme
apyrase degrades ATP to ADP, and ADP to AMP. In the
presence of this enzyme, OAG application failed to induce
calcium oscillations (Figure 2(b)). These results all appeared
reversible upon the reapplication of OAG following washout,
as summarized in Figure 2(c). Thus, the OAG-induced
calcium oscillations result from the stimulation of astrocytic
ATP receptors following astrocytic ATP release.
3.5. Astrocytic ATP Release Is Not Mediated by DAG Metabo-
lites. The enzyme DAG kinase metabolizes DAG to phos-
phatidic acid (for review see [25]). DAG lipase metabolizes
DAG to arachidonic acid [26]. Both of these small molecules
have putative signaling capabilities [27]. However, OAG-
induced calcium oscillations were not blocked by antagonists
of either DAG lipase or DAG kinase. Upon observing the
robust response to the 100µM concentration of OAG in
these studies, I decided to use the more moderate dose
of 30µM, which allowed us to see if there was either an
incremental or detrimental eﬀect of the pharmacological
reagents tested. Treating cells with the DAG kinase inhibitor
R59949 (10µM) enhances calcium oscillations caused by
the lower dose (30µM) of OAG (Figure 3). Treatment with
the DAG lipase inhibitor RHC80267 (50µM) had no eﬀect.
These data indicate that it is DAG itself, rather than one of its
metabolites, which is primarily responsible for ATP release.
3.6. OAG-Induced ATP Release Is Independent of PKC.
Protein kinase C can be activated by DAG via its C1
domain and has been implicated in the modulation of
exocytosis via the phosphorylation of proteins with roles
in vesicle docking, priming, and fusion [28]. I used several
pharmacological approaches to examine the role of PKC
in OAG-induced astrocytic ATP release. Staurosporine is a
general serine/threonine protein kinase inhibitor that blocks
the ATP-binding domain of PKC as well as other kinases
including protein kinase A and MAP kinase [29]. The
bisindolylmaleimide GF 109203X (GFX) is a potent and
selective inhibitor of protein kinase C that acts speciﬁcally
at the ATP binding site [30]. Calphostin C interferes with the
DAG-binding C1 domain of PKC, as well as of other proteins
containing this domain [31].
Adding GFX at time 2 had no eﬀect on the response of
astrocytes to OAG (Figure 4(a)). However, a recent report
found that previous activation of PKC with a phorbol ester
may render it active even in the presence of GFX [32].
When I pretreated cells with GFX, before OAG applica-
tion, there was still no eﬀect upon OAG-induced calcium
oscillations (Figure 4(a)). Staurosporine application alsohad
no response. During calphostin C application, there was a
gradual increase in the calcium signal (Figure 4(c)). This was
abolished by incubation in nominally calcium-free external
NHS (Figure 4(d)), indicating that the signal was a result of
an inﬂux of external calcium, perhaps via TRPC channels,
w h i c hc a nb ea c t i v a t e db yD A Gb u td on o tc o n t a i nC 1
domains [33, 34]. Cultured astrocytes respond to OAG in
calcium-free external NHS with oscillations (Figures 1(b)
and 4(b)). However, treatment with calphostin C abolished
this response (Figure 4(d); summarized in Figure 4(e)).
Thus, speciﬁc inhibition of PKC did not aﬀect astrocytic
ATP release, but inhibition of proteins containing C1 DAG-
binding domains abolished the response to OAG.
3.7. Mechanisms of ATP Release from Astrocytes. An u m b e ro f
mechanisms have been suggested for the release of ATP from
astrocytes. Two of the most likely under normal physiologic
conditions are the release of ATP via vesicular exocytosis
[1, 35–37] and regulated release via hemichannels [38, 39].
Baﬁlomycin is an inhibitor of the vesicular H+ ATPases that
set up the proton gradients necessary for vesicle ﬁlling [40]
and is a drug commonly used to probe exocytotic mecha-
nisms. Preincubation with baﬁlomycin A1 to deplete vesicles
and prevent vesicle ﬁlling greatly diminished OAG-induced
astrocytic ATP release (Figure 5(a)). The calcium response
to 1µM ATP was not changed by baﬁlomycin treatment,
indicating that the astrocytic ATP receptors were not aﬀected
by this treatment (Figure 5(b)). This indicates that vesicular
release is a likely mechanism underlying the OAG-inducedNeural Plasticity 7
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Figure 4: PKC activation is not necessary for OAG-induced release of ATP from astrocytes. (a) Adding 1µM GF 109203X (GFX) during the
second imaging period does not reduce calcium oscillations (P = 0.3, control n = 8, GFX n = 5) in response to 100µM OAG. Pretreating
astrocytes with 1µM GFX and including GFX during t1a n dt2 does not reduce calcium oscillations induced by 100µMO A G( P = 0.14,
control n = 8, GFX = 5), although there is a signiﬁcant (P = 0.03) increase in calcium oscillations after washout in this GFX condition. The
serine/threonine kinase inhibitor staurosporine does not have an eﬀect on calcium oscillations induced by 100µM OAG when added during
t2(P = 0.36, controln = 7,staurosporine n = 4).(b)Astrocytesdisplay robustOAG-induced calcium oscillations innominallycalcium-free
external solution. (c) Incubation with 100nM Calphostin C during a 15-minute light activation period followed by incubation during t2
abolishedcalciumoscillationandinducedaslowincreaseinFluo4signalduringtheOAGincubation.(d)TheslowincreaseinFluo4signalis
abolishedintheabsenceofexternalcalciumandoscillationsareabsentinthepresenceof100nMCalphostinCand30µMO A G.(e)C alcium
oscillations in nominally calcium-free medium induced by 30µM OAG are signiﬁcantly reduced by the addition of 100nM Calphostin C
(P = 0.004, control n = 5, calphostin C n = 4). As calphostin C is irreversible, there is no washout period (t3) for (e).
ATP release from cultured astrocytes. Hemichannels can
be selectively blocked by the glycyrrhetinic acid derivative
carbenoxolone [41–43]. Incubation with 50µMc a r b e n o x -
olone did not block OAG-induced ATP release in cultured
astrocytes (Figure 5(c)). Indeed, there was a signiﬁcant
increase in OAG-induced ATP release after incubation with
this hemi- and gap-junction blocker.
The inhibition of calcium oscillations by calphostin C
suggests that astrocytic ATP release is mediated via a DAG-
binding protein other than PKC. The Munc13-1 protein8 Neural Plasticity
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Figure 5: OAG-induced ATP release from astrocytes appears to be vesicular. (a) Incubation of cultured astrocytes with 100nM Baﬁlomycin
A1, an inhibitor of the vesicular H+ ATPases that set up the proton gradients necessary for vesicle ﬁlling, greatly reduced OAG-induced
astrocytic ATP release (baﬁlomycin n = 8, control n = 5; t1 P = 0.01, t2 P = 0.02, t3 n = 0.004). This eﬀect was partially washed out
after 15 minutes (t2b a fv e r s u st3w a s hP = 0.024). (b) Baﬁlomycin treatment did not aﬀect the function of astrocytic ATP receptors, as
the calcium response to 1µM ATP was unaﬀected by baﬁlomycin treatment (baﬁlomycin n = 5, control n = 5, P = 0.9). (c) The gap
junction and hemichannel blocker carbenoxolone (CBX), at 50µM, resulted in an increase in astrocytic ATP release (control n = 14, CBX
n = 5; t2 P = 0.03, t3 P = 0.02).
has been shown to be crucial for transmitter release from
cell types including chromaﬃn cells and neurons [44–46].
Munc13-1 has been shown to potentiate neurotransmitter
release via both PKC-dependent and independent pathways
followingDAGactivation[32].IshowthatMunc13-1mRNA
and protein are expressed in cultured cortical astrocytes
(Figures 6(a)–6(c)). siRNas designed against Munc13-1 were
able to reduce Munc13-1 protein content, as measured
via Western blot in cultured astrocytes, by about 30%
(Figure 6(d)). This modest siRNA-mediated reduction of
Munc13-1 likely reﬂects its rapid turnover rate [47]. The
reduction of Munc13-1 in astrocytes signiﬁcantly reduces
OAG-induced astrocytic ATP release (Figure 6(e)) impli-
cating this protein in exocytotic release of ATP from
astrocytes.
4. Discussion
The current work seeks to elucidate the pathway linking the
activationofGq-coupledreceptorstogliotransmissioninthe
astrocytes. I have shown, using in vitro live imaging, that
stimulation of the DAG pathway with the DAG analogue,
OAG, results in ATP release that appears to be both PKC
independent and vesicular. Furthermore, I have shown
evidenceimplicatingtheMunc13-1exocytoticproteininthis
novel mechanism.
Following my initial observation that the application
of OAG led to ATP release from astrocytes, as measured
directly via luminometry, I primarily used calcium imaging
as an indirect measurement of astrocytic ATP release.
This has proven to be a reliable and robust indicatorNeural Plasticity 9
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Figure 6: The Munc13-1 protein is expressed in cultured astrocytes and reduction of Munc13-1 expression reduces astrocytic ATP release.
(a) Immunocytochemistry for Munc13-1 in cultured astrocytes demonstrates expression of Munc13-1 in these cells: (green: Munc13-1,
blue: DAPI). (b) Western blotting for Munc13-1 demonstrates a band at the expected size (∼200kD). Gel lanes were loaded with 60µgo f
cultured mouse astrocyte protein or 15µg of protein extracted from cultured mouse cortical neurons. (c) RT-PCR with primers designed
against Munc13-1 of whole mouse brain mRNA and mRNA extracted from cultured astrocytes demonstrated a band for Munc13-1 at the
expected size. Sequencing of these bands conﬁrmed the presence of Munc13-1 in cultured astrocytes. (d) siRNAs designed against mouse
Munc13-1 reduce the expression of Munc13-1 in transfected mouse astrocytes as measured by Western blot. Optical density of the Munc13-
1 signal was standardized against the housekeeping protein GAPDH (scrambled siRNA n = 4, Munc13-1 siRNA = 4, P = 0.05). (e) The
response of cultured astrocytes to OAG during one imaging session was measured for cultured astrocytes transfected with either scrambled
control siRNAs or siRNAs directed against the Munc13-1 mRNA. The percentage of cells responding to OAG was signiﬁcantly reduced after
transfection with Munc13-1 siRNA (scrambled siRNA n = 6, Munc13-1 siRNA = 9; P = 0.017).10 Neural Plasticity
of ATP release in these cells (for review see [48]), and
pharmacological reagents can be easily washed via a tightly
controlled perfusion system. Two concentrations of OAG
reliably induced calcium oscillations in cultured astrocytes.
Theseoscillationswereobservedinindividualcellsindistinct
areas of the culture; calcium waves were not observed upon
OAG application Supplemental Figure 1. Calcium waves in
cultured astrocytes have been attributed to ATP released
acting upon the ATP receptors of neighboring astrocytes
[49]. Because the ATP released in these studies did not
trigger calcium waves in the conﬂuent cultures I imaged, I
can assume that the amounts released were very small, and
fed back onto ATP receptors no further distant than the
immediate cell concerned.
Previous work conﬁrmed that OAG-induced astrocyte
calcium oscillations are PLC dependent [19]. The use of
PPADS combined with suramin to block P2 receptors
allowed us to observe that the OAG-induced oscillations
were dependent upon functional ATP receptors. Combined
with the use of apyrase, which metabolizes ATP to ADP
and ADP to AMP, these data indicate that the OAG-
induced calcium oscillations are being mediated by ATP
acting upon P2 receptors to mobilize calcium from internal
stores. The calcium responsible for the Fluo4 ﬂuorescence
was not coming from the external solution, as OAG-induced
oscillations persisted in the absence of external calcium.
T h e r ea r ean u m b e ro fp a t h w a y sd o w n s t r e a mo ft h ec o n -
version of PLC into DAG and IP3. Following the production
of DAG, it is possible for this molecule to bind to the C1
domains of PKC [50], Munc13, DAG Kinase, chimaerin, and
Ras GRPs (for review see [51]). DAG can also bind proteins,
suchasDAGlipaseandmembraneTRPchannels[34],which
do not contain C1 domains. DAG kinase and DAG lipase
metabolize DAG to phosphatidic acid and arachidonic acid,
respectively[25,26].Bothofthesemetaboliteshavesignaling
capabilities [27]. The inhibition of either enzyme did not
perturb the response of the astrocytes to OAG in these
studies. Thus, neither arachidonic acid nor phosphatidic
acid is necessary for the OAG-induced ATP release. OAG
is likewise a substrate for both of these enzymes; therefore
the lack of eﬀect is not from a lack of these metabolites.
The increase of the OAG-induced ATP release induced via
inhibition of DAG kinase with R59949 suggests that DAG
kinase is the more predominant metabolic enzyme for DAG
in cultured cortical astrocytes.
DAG activation of PKC has long been known to poten-
tiate synaptic function [52–55]. The bisindolylmaleimide GF
109203X (GFX) is a potent and selective inhibitor of both
classical and novel PKC isoforms [30, 56]. In the current
study, neither pretreatment nor regular application of GFX
prevented OAG-induced ATP release. Application of the C1
domain inhibitor calphostin C in normal external medium
caused an inﬂux of external calcium. This could be due to
the actions of OAG and endogenous DAG upon astrocytic
TRPC channels, which bind DAG but do not contain a C1
domain [33]. In nominally calcium-free external medium,
the calcium inﬂux is prevented. Although OAG normally
stimulates ATP release in the presence of calcium-free exter-
nal medium, this OAG-dependent ATP release is blocked by
calphostinC.DAGpotentiationofsynapticvesiclereleasehas
also been suggested to be, in some cases, PKC independent
and Munc13-1 dependent [57]. Munc13-1 potentiation of
transmitter release in neurons may also rely upon previous
phosphorylation of the Munc18 protein by PKC [32]. I show
herethatDAGappearstopotentiateATPreleaseinastrocytes
independent of PKC.
The baﬁlomycin data presented in this study support a
vesicular release of ATP downstream of OAG stimulation in
cultured astrocytes. However, astrocytes have also been pur-
ported to release ATP via connexin or pannexin hemichan-
nels [38, 58, 59]. After blocking astrocytic hemichannels
with carbenoxolone, I found that the OAG-induced ATP
release from cultured astrocytes was not diminished but
instead was signiﬁcantly enhanced. While this result argues
against hemichannel ATP release being induced by OAG, the
augmentation of the eﬀect with carbenoxolone is intriguing.
Perhaps, as carbenoxolone also blocks intercellular gap
junctions [41], IP3 is unable to diﬀuse to coupled cells [60]
and thus more calcium is released from intracellular stores.
Alternatively, the inhibition of intercellular gap junctions
may also prevent the diﬀusion of cytosolic ATP between
conﬂuent astrocytes [61], increasing the availability of ATP
for uptake into vesicles.
TheroleofRhoGTPasesinnonexocytoticastrocyticATP
release has been examined [62]. Utilizing an astrocytoma
cell line, the authors implicated Rho GTPases as an eﬀector
of hemichannel ATP release downstream of Gq activation.
While this is an intriguing possibility, my studies knocking
down Munc13-1 expression in primary conﬂuent astrocytes
direct attention towards that protein as being involved in
astrocytic ATP release. The signiﬁcant reduction in ATP
release I ﬁnd, upon a relatively modest siRNA-mediated
reduction in Munc13-1 expression, implies that ATP release
may be tightly controlled by Munc13-1 in astrocytes. It
has previously been shown that astrocytic ATP release
is impaired by the disruption of the SNARE exocytotic
machinery [1], which interacts with the MUN domain of
Munc13-1 in neurons [63]. The data presented in this work
concur with a vesicular release of ATP in astrocytes and
provide evidence for a DAG/Munc13 pathway linking Gq
signaling in astrocytes with ATP gliotransmission.
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